ProCE Banner Activity

Current and Future Roles of BCMA-Targeted Therapies for Multiple Myeloma

Clinical Thought
Learn how experts incorporate BCMA-directed therapies for multiple myeloma into their practice.

Released: February 02, 2022

Expiration: February 01, 2023

Share

Faculty

Nina Shah

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received funds for research support from Bluebird, Celgene/Bristol-Myers Squibb, Nektar, Poseida, Precision, Sutro, and Teneobio and consulting, advisor, and speaker fees from Amgen, CareDX, CSL Behring, GlaxoSmithKline, Indapta, Karyopharm, Kite, Oncopeptides, and Sanofi.